Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "Chronic Kidney Disease Anemia: Opportunity Assessment and Forecast" report has been added to ResearchAndMarkets.com's offering. This report covers the ...

With the skyrocketing popularity of GLP-1 RAs, some lesser-known side effects, including anemia, are coming to light.

Modus Therapeutics Holding AB has announced that the first patient has been dosed in part 2 of its ongoing phase 2a clinical study evaluating sevuparin for the treatment of chronic kidney disease (CKD ...

Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and ...

Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and TaiGen Biotechnology, a listed discovery-based and market-focused ...

STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio ...

Modus Therapeutics Holding AB (“Modus”) today announces that the first patient has been dosed in Part 2 of the company’s ongoing Phase IIa clinical study evaluating sevuparin for the treatment of ...

Dexoligo Therapeutics has presented data for their liver-targeted siRNA DXO-1801 for the potential treatment of inflammation-driven anemia, a serious complication of chronic diseases such as chronic ...

A new study published in the journal of Nature Scientific Reports showed that patients with end-stage renal disease (ESRD) ...

In a real-world study, UPCR decreased when darbepoetin alfa dose exceeded 60 μg in patients with diabetic kidney disease. Darbepoetin alfa treatment is associated with proteinuria lowering in a ...